H.R. 2672 · 112th Congress
Preserving Access to Orphan Drugs Act of 2011
- Stage
- In committee
- Sponsor
- Jim Gerlach
- Introduced
- 2011-07-27
- Latest action
- 2011-08-01 · Referred to the Subcommittee on Health.
Summary
Preserving Access to Orphan Drugs Act of 2011 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.
Makes this Act effective as if included in PPACA.